ヒュミラ・バイオシミラーの世界市場レポート 2025年

ヒュミラ・バイオシミラーの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12.6%で59億6,000万米ドルに成長します。今後の見通しとしては、バイオシミラー開発技術の進歩、ヘルスケアコスト抑制への取り組みの強化、先発生物製剤の特許切れ、市場参入と償還政策の改善、腫瘍学と自己免疫疾患におけるバイオシミラーの採用増加などが予測期間の成長を牽引するとみられます。この期間に予想される主な動向には、バイオシミラーの追加承認の増加、製造技術の進歩、研究開発活動の拡大、バイオシミラー新薬の開発と承認、製剤の革新などがあります。

自己免疫疾患の有病率の増加は、ヒュミラ・バイオシミラー市場の拡大を促進すると予想されます。自己免疫疾患は、免疫系が誤って健康な細胞や組織、臓器を攻撃することで発生します。このような症例の増加は、免疫系の機能を混乱させ、自己免疫反応のリスクを高める環境汚染との関連性が高まっています。ヒュミラバイオシミラーは、自己免疫疾患において炎症を引き起こす原因となるタンパク質である腫瘍壊死因子（TNF）を阻害することにより機能します。TNFを阻害することにより、これらのバイオシミラーは免疫系の過剰な活性を抑え、症状を緩和し、健康な組織への損傷を防ぐことができます。例えば、2024年6月、オーストラリア保健福祉研究所は、2022年に推定51万4,000人のオーストラリア人（人口の2.0％）が関節リウマチを患っていると報告しました。その結果、自己免疫疾患の罹患率が上昇し、ヒュミラのバイオシミラーの需要を押し上げています。

ヒュミラ・バイオシミラー市場の主要プレーヤーは、自己免疫疾患の治療アクセス性を向上させるため、費用対効果の高いTNF遮断療法の開発に注力しています。TNF遮断薬はTNFの作用を阻害する生物学的製剤であり、炎症と疾患症状を軽減します。例えば、2023年7月、米国の製薬会社であるオルガノン社は、韓国のバイオテクノロジー企業であるサムスンバイオエピス社と提携し、ヒュミラ・バイオシミラーであるHADLIMAを発売しました。HADLIMAには、クエン酸塩を含まない高濃度製剤（100mg/mL）とクエン酸塩を含む低濃度製剤（50mg/mL）があり、ヒュミラと同様の選択肢があります。ヒュミラは先発品の定価より約85％低い価格で提供され、患者支援プログラムによりサポートされています。今回の上市は世界な和解により認められたもので、米国における自己免疫治療薬の価格とアクセスを大幅に向上させるものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のヒュミラ・バイオシミラーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のヒュミラ・バイオシミラー市場：成長率分析
• 世界のヒュミラ・バイオシミラー市場の実績：規模と成長、2019年～2024年
• 世界のヒュミラ・バイオシミラー市場の予測：規模と成長、2024年～2029年、2034年
• 世界のヒュミラ・バイオシミラー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のヒュミラ・バイオシミラー市場：製品タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• アダリムマブバイオシミラー
• その他のタイプ
• 世界のヒュミラ・バイオシミラー市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界のヒュミラ・バイオシミラー市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 関節リウマチ
• 乾癬
• クローン病
• 潰瘍性大腸炎
• 強直性脊椎炎
• その他の用途
• 世界のヒュミラ・バイオシミラー市場、アダリムマブバイオシミラーの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 完全ヒトモノクローナル抗体
• フラグメント結晶化領域（Fc領域）を改変したバイオシミラー
• 高濃度製剤
• クエン酸フリー処方
• 世界のヒュミラ・バイオシミラー市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 他の腫瘍壊死因子（TNF）阻害剤のバイオシミラー
• 互換性のあるバイオシミラー
• ペグ化バイオシミラー
• アダリムマブ以外のモノクローナル抗体バイオシミラー

第7章 地域別・国別分析

• 世界のヒュミラ・バイオシミラー市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のヒュミラ・バイオシミラー市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ヒュミラ・バイオシミラー市場：競合情勢
• ヒュミラ・バイオシミラー市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • LG Chem Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim GmbH
• Mylan N.V.
• Sandoz Group AG
• Fresenius Kabi AG
• Celltrion Inc.
• Biocon Limited
• Torrent Pharmaceuticals
• Samsung Bioepis Co. Ltd.
• Alvotech
• Coherus BioSciences Inc.
• Zydus Cadila
• Hetero Drugs Ltd.
• Fujifilm Kyowa Kirin Biologics
• Synermore Biologics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ヒュミラ・バイオシミラー市場2029年：新たな機会を提供する国
• ヒュミラ・バイオシミラー市場2029年：新たな機会を提供するセグメント
• ヒュミラ・バイオシミラー市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A Humira biosimilar is a biologic drug developed to closely replicate Humira in the treatment of autoimmune disorders. It mirrors the original in terms of safety, effectiveness, and quality but is generally more affordable. By offering a cost-effective alternative, these biosimilars improve patient access to treatment while helping to reduce overall healthcare expenses.

The primary product types of Humira biosimilars include adalimumab biosimilars and others. Adalimumab biosimilars are biologic medications that closely resemble the reference anti-TNF drug Humira, offering equivalent safety, effectiveness, and quality in the treatment of autoimmune conditions. These biosimilars are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used for a range of conditions including rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and more.

The humira biosimilars market research report is one of a series of new reports from The Business Research Company that provides humira biosimilars market statistics, including the humira biosimilars industry global market size, regional shares, competitors with the humira biosimilars market share, detailed humira biosimilars market segments, market trends, opportunities, and any further data you may need to thrive in the humira biosimilars industry. This humira biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The humira biosimilar market size has grown rapidly in recent years. It will grow from $3.28 billion in 2024 to $3.70 billion in 2025 at a compound annual growth rate (CAGR) of 13.0%. The growth observed during the historic period can be attributed to the increasing demand for cost-effective alternatives, rising approval of biosimilars by regulatory bodies, the growing prevalence of autoimmune diseases, expanding healthcare access in emerging markets, and the high cost of original biologic drugs.

The humira biosimilar market size is expected to see rapid growth in the next few years. It will grow to $5.96 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. Looking ahead, growth in the forecast period is expected to be driven by advancements in biosimilar development technologies, increasing efforts to contain healthcare costs, the expiration of patents for original biologics, improvements in market access and reimbursement policies, and the rising adoption of biosimilars in oncology and autoimmune diseases. Key trends expected during this period include the increasing approval of additional biosimilars, advancements in manufacturing technologies, expanding research and development activities, the development and approval of new biosimilar drugs, and innovations in drug formulations.

The growing prevalence of autoimmune diseases is expected to drive the expansion of the Humira biosimilar market. Autoimmune diseases arise when the immune system mistakenly attacks healthy cells, tissues, or organs. This rise in cases is increasingly linked to environmental pollution, which can disrupt immune system function and elevate the risk of autoimmune reactions. Humira biosimilars function by blocking tumor necrosis factor (TNF), a protein responsible for causing inflammation in autoimmune conditions. By inhibiting TNF, these biosimilars help reduce the immune system's overactivity, relieve symptoms, and prevent damage to healthy tissue. For instance, in June 2024, the Australian Institute of Health and Welfare reported that an estimated 514,000 Australians (2.0% of the population) were living with rheumatoid arthritis in 2022, including 2.5% of females and 1.6% of males. As a result, the rising incidence of autoimmune diseases is boosting demand for Humira biosimilars.

Key players in the Humira biosimilar market are focused on advancing cost-effective TNF-blocking therapies to improve treatment accessibility for autoimmune diseases. TNF blockers are biologic medications that inhibit the action of TNF, reducing inflammation and disease symptoms. For example, in July 2023, Organon & Co., a U.S.-based pharmaceutical company, partnered with Samsung Bioepis, a South Korea-based biotech firm, to launch HADLIMA, a Humira biosimilar. HADLIMA is available in both citrate-free high-concentration (100 mg/mL) and citrate-containing low-concentration (50 mg/mL) formulations, mirroring the original Humira options. It is offered at a price approximately 85% lower than the originator's list price and is supported by patient assistance programs. This launch, permitted by a global settlement, significantly enhances affordability and access to autoimmune treatments in the U.S.

In February 2024, Alvotech, a Luxembourg-based biotech company, partnered with Teva Pharmaceuticals to introduce SIMLANDI, the first high-concentration, citrate-free interchangeable Humira biosimilar in the U.S. The collaboration aims to expand access to affordable adalimumab therapy, stimulate biosimilar market competition, and improve treatment outcomes for patients with chronic autoimmune diseases. Teva Pharmaceuticals is a U.S.-based pharmaceutical company.

Major players in the humira biosimilar market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., LG Chem Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Mylan N.V., Sandoz Group AG, Fresenius Kabi AG, Celltrion Inc., Biocon Limited, Torrent Pharmaceuticals, Samsung Bioepis Co. Ltd., Alvotech, Coherus BioSciences Inc., Zydus Cadila, Hetero Drugs Ltd., Fujifilm Kyowa Kirin Biologics, Synermore Biologics, and CVS Health.

North America was the largest region in the humira biosimilar market in 2024. The regions covered in humira biosimilar report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the humira biosimilar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The humira biosimilar market consists of sales of prefilled syringes, autoinjector (AI) pens, and vials. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Humira Biosimilar Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on humira biosimilar market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for humira biosimilar ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The humira biosimilar market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Adalimumab Biosimilars; Other Types
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 3) By Application: Rheumatoid Arthritis; Psoriasis; Crohn's Disease; Ulcerative Colitis; Ankylosing Spondylitis; Other Applications
• Subsegments:
• 1) By Adalimumab Biosimilars: Fully Human Monoclonal Antibodies; Fragment Crystallizable (Fc) Region Modified Biosimilars; High-Concentration Formulations; Citrate-Free Formulations
• 2) By Other Types: Biosimilars Of Other Tumor Necrosis Factor (TNF) Inhibitors; Interchangeable Biosimilars; Pegylated Biosimilars; Non-Adalimumab Monoclonal Antibody Biosimilars
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; LG Chem Ltd.; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Humira Biosimilar Market Characteristics

3. Humira Biosimilar Market Trends And Strategies

4. Humira Biosimilar Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Humira Biosimilar Growth Analysis And Strategic Analysis Framework

• 5.1. Global Humira Biosimilar PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Humira Biosimilar Market Growth Rate Analysis
• 5.4. Global Humira Biosimilar Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Humira Biosimilar Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Humira Biosimilar Total Addressable Market (TAM)

6. Humira Biosimilar Market Segmentation

• 6.1. Global Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adalimumab Biosimilars
• Other Types
• 6.2. Global Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.3. Global Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rheumatoid Arthritis
• Psoriasis
• Crohn's Disease
• Ulcerative Colitis
• Ankylosing Spondylitis
• Other Applications
• 6.4. Global Humira Biosimilar Market, Sub-Segmentation Of Adalimumab Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fully Human Monoclonal Antibodies
• Fragment Crystallizable (Fc) Region Modified Biosimilars
• High-Concentration Formulations
• Citrate-Free Formulations
• 6.5. Global Humira Biosimilar Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biosimilars of Other Tumor Necrosis Factor (TNF) Inhibitors
• Interchangeable Biosimilars
• Pegylated Biosimilars
• Non-Adalimumab Monoclonal Antibody Biosimilars

7. Humira Biosimilar Market Regional And Country Analysis

• 7.1. Global Humira Biosimilar Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Humira Biosimilar Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Humira Biosimilar Market

• 8.1. Asia-Pacific Humira Biosimilar Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Humira Biosimilar Market

• 9.1. China Humira Biosimilar Market Overview
• 9.2. China Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Humira Biosimilar Market

• 10.1. India Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Humira Biosimilar Market

• 11.1. Japan Humira Biosimilar Market Overview
• 11.2. Japan Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Humira Biosimilar Market

• 12.1. Australia Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Humira Biosimilar Market

• 13.1. Indonesia Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Humira Biosimilar Market

• 14.1. South Korea Humira Biosimilar Market Overview
• 14.2. South Korea Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Humira Biosimilar Market

• 15.1. Western Europe Humira Biosimilar Market Overview
• 15.2. Western Europe Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Humira Biosimilar Market

• 16.1. UK Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Humira Biosimilar Market

• 17.1. Germany Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Humira Biosimilar Market

• 18.1. France Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Humira Biosimilar Market

• 19.1. Italy Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Humira Biosimilar Market

• 20.1. Spain Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Humira Biosimilar Market

• 21.1. Eastern Europe Humira Biosimilar Market Overview
• 21.2. Eastern Europe Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Humira Biosimilar Market

• 22.1. Russia Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Humira Biosimilar Market

• 23.1. North America Humira Biosimilar Market Overview
• 23.2. North America Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Humira Biosimilar Market

• 24.1. USA Humira Biosimilar Market Overview
• 24.2. USA Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Humira Biosimilar Market

• 25.1. Canada Humira Biosimilar Market Overview
• 25.2. Canada Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Humira Biosimilar Market

• 26.1. South America Humira Biosimilar Market Overview
• 26.2. South America Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Humira Biosimilar Market

• 27.1. Brazil Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Humira Biosimilar Market

• 28.1. Middle East Humira Biosimilar Market Overview
• 28.2. Middle East Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Humira Biosimilar Market

• 29.1. Africa Humira Biosimilar Market Overview
• 29.2. Africa Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Humira Biosimilar Market Competitive Landscape And Company Profiles

• 30.1. Humira Biosimilar Market Competitive Landscape
• 30.2. Humira Biosimilar Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. LG Chem Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Humira Biosimilar Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Boehringer Ingelheim GmbH
• 31.3. Mylan N.V.
• 31.4. Sandoz Group AG
• 31.5. Fresenius Kabi AG
• 31.6. Celltrion Inc.
• 31.7. Biocon Limited
• 31.8. Torrent Pharmaceuticals
• 31.9. Samsung Bioepis Co. Ltd.
• 31.10. Alvotech
• 31.11. Coherus BioSciences Inc.
• 31.12. Zydus Cadila
• 31.13. Hetero Drugs Ltd.
• 31.14. Fujifilm Kyowa Kirin Biologics
• 31.15. Synermore Biologics

32. Global Humira Biosimilar Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Humira Biosimilar Market

34. Recent Developments In The Humira Biosimilar Market

35. Humira Biosimilar Market High Potential Countries, Segments and Strategies

• 35.1 Humira Biosimilar Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Humira Biosimilar Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Humira Biosimilar Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer